School of Medicine
Colorectal cancer is the second most common cause of cancer deaths for both men and women, and the third most common cause of cancer in the U.S. Toxicity of current chemotherapeutic agents for colorectal cancer, and emergence of drug resistance underscore the need to develop new, potentially less toxic alternatives. Our recent cross-sectional study in a large Appalachian population, showed a strong, inverse, dose–response association of serum perfluorooctane sulfonate (PFOS) levels to prevalent colorectal cancer, suggesting PFOS may have therapeutic potential in the prevention and/or treatment of colorectal cancer. In these preliminary studies using a mouse model of familial colorectal cancer, the APCmin mouse, and exposures comparable to those reported in human populations, we assess the efficacy of PFOS for reducing tumor burden, and evaluate potential dose–response effects.
Digital Commons Citation
Wimsatt, Jeffrey; Villers, Meghan; Thomas, Laurel; Kamarec, Stacey; Montgomery, Caitlin; Yeung, Leo W. Y.; Hu, Yanqing; and Innes, Kim, "Oral Perfluorooctane Sulfonate (PFOS) Lessens Tumor Development In The APCmin Mouse Model of Spontaneous Familial Adenomatous Polyposis" (2016). Faculty & Staff Scholarship. 1483.
Wimsatt, J., Villers, M., Thomas, L., Kamarec, S., Montgomery, C., Yeung, L. W. Y., Hu, Y., & Innes, K. (2016). Oral perfluorooctane sulfonate (PFOS) lessens tumor development in the APCmin mouse model of spontaneous familial adenomatous polyposis. BMC Cancer, 16(1). https://doi.org/10.1186/s12885-016-2861-5